Exagen Q3: Revenue Up 7% to $18.4M, Cash Slips to $28.1M as New $50M ATM Launches
XGN has more than doubled off its 52-week low of $2.59 on elevated volume (2.0× avg).
Summary
Exagen grew Q3 revenue 6.8% to $18.4M but burned cash down to $28.1M, and paired the report with a $5.0M debt draw and a new $50M at-the-market stock program.
Key Events · Earnings and Guidance · XGN
-
Q3 Revenue Grows 6.8% to $18.4M
Revenue rose to $18.4M from $17.2M a year earlier, with AVISE CTD test volume up about 2% and trailing-twelve-month ASP up 2% to $451 per test.
-
Loss Widens on Non-Cash Items
Net loss was $6.3M ($0.25 per share) versus $7.1M a year ago. The quarter included a $0.9M non-cash warrant fair-value charge and $0.6M of expensed acquired IPR&D, leaving a $4.4M operating loss.
-
Cash Falls to $28.1M
Cash and equivalents dropped to $28.1M at September 30 from $32.2M at December 31, 2025, against a $327.8M accumulated deficit; management says resources fund at least twelve months.
-
New $50M ATM and $150M Shelf
A November 9 sales agreement with TD Cowen allows up to $50.0M of stock sales at a 3.0% commission, and a new $150.0M shelf was filed November 10 before the 2023 shelf expires November 29, 2026.
Analysis · XGN · Industrial Applications And Services
Revenue growth is real but slowing: Q3's 6.8% gain to $18.4M trails the 11.5% pace of the first nine months. The $6.3M quarterly loss was inflated by a $0.9M non-cash warrant remeasurement and $0.6M of expensed acquired IPR&D, so the underlying operating loss was $4.4M. The balance sheet is the story. Cash fell to $28.1M from $32.2M at year-end, and management's own twelve-month runway claim now leans on the $5.0M Tranche B draw taken November 9 plus a freshly signed $50M at-the-market program. That ATM, paired with a new $150M shelf filed November 10 ahead of the old shelf's November 29 expiry, means dilution overhang is now the default funding path.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XGN was trading at $6.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $172M. The 52-week trading range was $2.59 to $10.41. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.